Skip to main content
SpringerLink
Log in

A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice

  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

In the present study, we examined the effects of a newly developed bisphosphonate, minodronate (YM529), on osteolytic bone metastasis caused by lung cancer. Human small-cell lung cancer (SBC-5) cells, injected intravenously into natural killer cell-depleted SCID mice, produced radiologically detectable bone metastasis by day 18 and macroscopically visible visceral metastases (lung, liver, kidney, systemic lymph node) by day 35. Prophylactic treatment with YM529 on day 1 significantly inhibited the formation of osteolytic bone metastasis evaluated on X-ray photographs in a dose-dependent manner. In addition, treatment with YM529 after establishment of bone metastasis (on day 21) also inhibited bone metastasis, although the treatment was more effective when started earlier. Single administration was as effective as repeated treatment, suggesting a sustained inhibitory effect of YM529 on bone metastasis. YM529 reduced the number of osteoclasts in the bone metastatic lesions in vivo, but had no effect on the proliferation or cytokine production of SBC-5 cells in vitro. These results suggest that YM529 is a potent inhibitor of bone metastasis of human lung cancer, probably by suppressing osteoclastic bone resorption. In contrast, treatment with YM529 had no effect on visceral metastasis, even if started on day 1, and did not prolong the survival of the mice. Therefore, development of a combined modality is necessary for prolonging the survival of small-cell lung cancer patients with multiple-organ metastasis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ishikawa H, Satoh H, Kurishima K et al. Lung cancer with synchronous brain and bone metastasis. Clin Oncol (R Coll Radiol) 2000; 12: 136–7.

    CAS  Google Scholar 

  2. Quint LE, Francis IR, Wahl RL et al. Imaging of lung cancer. In Pas HI, Mitchells JB, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven 1996; 437–70.

    Google Scholar 

  3. Yano S, Nishioka Y, Izumi K et al. Novel metastasis model of human lung cancer in SCID mice depleted of NK cells. Int J Cancer 1996; 67: 211–7.

    Article  PubMed  CAS  Google Scholar 

  4. Sullivan FJ.Palliative radiotherapy for lung cancer. In Pass HI, Mitchell JB, Johnson DH, Turrisi AT (eds): Lung Cancer: Principles and Practice. Philadelphia: Lippincott-Raven 1996; 775–89.

  5. Theriault RL, Hortobagyi GN. The evolving role of bisphosphonates. Semin Oncol 2001; 28: 284–90.

    Article  PubMed  CAS  Google Scholar 

  6. Body JJ, Barttl R, Burckhardt P et al. Current use of bisphosphonates in oncology. J Clin Oncol 1998; 16: 3890–9.

    PubMed  CAS  Google Scholar 

  7. Rizzoli R, Forni M, Schaad MA et al. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer. Bone 1996; 18: 531–7.

    Article  PubMed  CAS  Google Scholar 

  8. Smith JA Jr. Palliation of painful bone metastases from prostate cancer using sodium etidronate: Results of a randomized, prospective, double-blind, placebo-controlled study. J Urol 1989; 141: 85–7.

    PubMed  Google Scholar 

  9. Stearns ME, Wang M. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. Invasion Metastasis 1996; 16: 116–31.

    PubMed  CAS  Google Scholar 

  10. Yoneda T, Sasaki A, Dunstan C et al. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with YM529 inhibits osteolytic bone metastasis caused by lung cancer 159 the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2. J Clin Invest 1997; 99: 2509–17.

    Article  PubMed  CAS  Google Scholar 

  11. Theriault RL, Lipton A, Hortobagyi GN et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: A randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999; 17: 846–54.

    PubMed  CAS  Google Scholar 

  12. Berenson JR, Vescio RA, Rosen LS et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res 2001; 7: 478–85.

    PubMed  CAS  Google Scholar 

  13. Benford HL, Frith JC, Auriola S et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: Biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. Mol Pharmacol 1999; 56: 131–40.

    PubMed  CAS  Google Scholar 

  14. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997; 80 (Suppl): 1652–60.

    Article  PubMed  CAS  Google Scholar 

  15. Hillner BE, Ingle JN, Berenson JR et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol 2000; 18: 1378–91.

    Google Scholar 

  16. Sasaki A, Kitamura K, Alcalde RE et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. Int J Cancer 1998; 77: 279–85.

    Article  PubMed  CAS  Google Scholar 

  17. Miki T, Yano S, Hanibuchi Met al. Bone metastasis model with multiorgan dissemination of human small-cell lung cancer (SBC-5) cells in natural killer cell-depleted SCID mice. Oncol Res 2000; 12: 209–17.

    PubMed  CAS  Google Scholar 

  18. Hauschka PV, Manrakos AE, Iafrati MD et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 1986; 261: 12665–74.

    PubMed  CAS  Google Scholar 

  19. Pfeilschifter J, Mundy GR. Modulation of transforming growth factor beta activity in bone cultures by osteotropic hormones. Proc Natl Acad Sci USA 1987; 84: 2024–8.

    Article  PubMed  CAS  Google Scholar 

  20. Lee MV, Fong EM, Singer FR et al. Bisphosphonate treatment inhibit the growth of prostate cancer cells. Cancer Res 2001; 61: 2602–8.

    PubMed  CAS  Google Scholar 

  21. Senaratne SG, Pirianov G, Mansi JL et al. Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 2000; 82: 1459–68.

    PubMed  CAS  Google Scholar 

  22. Takahashi R, Shimazaki C, Inaba T et al. A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells. Leuk Res 2001; 25: 77–83.

    Article  PubMed  CAS  Google Scholar 

  23. Sasaki A, Boyce BF, Story B et al. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Res 1995; 55: 3551–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine and Molecular Therapeutics, Japan

    Helong Zhang, Seiji Yano, Toyokazu Miki, Hisatsugu Goto, Takanori Kanematsu, Hiroaki Muguruma, Hisanori Uehara & Saburo Sone

  2. Department of Molecular and Environmental Pathology, University of Tokushima School of Medicine, Tokushima, Japan

    Helong Zhang, Seiji Yano, Toyokazu Miki, Hisatsugu Goto, Takanori Kanematsu, Hiroaki Muguruma, Hisanori Uehara & Saburo Sone

Authors
  1. Helong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Seiji Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Toyokazu Miki
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hisatsugu Goto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Takanori Kanematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hiroaki Muguruma
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hisanori Uehara
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Saburo Sone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Saburo Sone.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zhang, H., Yano, S., Miki, T. et al. A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice. Clin Exp Metastasis 20, 153–159 (2003). https://doi.org/10.1023/A:1022621622063

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1022621622063

Search

Navigation